2-(1,3-dioxoisoindolin-2-yl)butanoyl chloride | 68468-16-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-(1,3-dioxoisoindolin-2-yl)butanoyl chloride
• 英文别名: 2-Phthalimidobuttersaeurechlorid；2-phthalimido-butyryl chloride；phthalimidobutyric chloride；2-(1,3-dioxoisoindol-2-yl)butanoyl chloride
• CAS: 68468-16-6
• 化学式: C₁₂H₁₀ClNO₃
• 分子量: 251.669
• InChiKey: ZPIDYMGRVSLNLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  54.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(1,3-dioxoisoindolin-2-yl)butanoyl chloride 在 乙醚 作用下， 生成 N-(3-acetoxy-1-ethyl-2-oxo-propyl)-phthalimide
  参考文献：
  名称：

  Balenovic et al., Croatica Chemica Acta, 1956, vol. 28, p. 231,234

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(1,3-二氧代-1,3-二氢-2H-异吲哚-2-基)-丁酸 在 草酰氯 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-(1,3-dioxoisoindolin-2-yl)butanoyl chloride
  参考文献：
  名称：

  钯/镍配合物催化的α-氨基酸衍生物的生物启发脱氨

  摘要：

  已经开发了一种有效的生物启发的天然和非天然氨基酸衍生物的脱氨方法。该方法可轻松获取各种有用的α，β-不饱和羰基化合物。通过两种易于操作的过渡金属催化剂（钯和镍）可以实现该反应。还提出了可能的反应途径，而控制实验则支持了钯催化的惰性sp 3 C-H活化的参与，这是关键步骤之一。

  DOI：

  10.1002/adsc.201800823

文献信息

• Acetazolamide-related compounds, process for their preparation, and
  申请人：Instituto Chimico Internazionale Dr. Giuseppe Rende S.r.l.

  公开号：US05010204A1

  公开（公告）日：1991-04-23

  Compounds related to acetazolamide and to its N-methyl derivatives, of the formulae: ##STR1## wherein Y is one of the following groups: ##STR2## R.sub.1 being a straight or branched alkylene or arylalkylene, or a phenylene, and the processes for their preparation; the compounds so obtained are inhibitors of carbonic anhydrase like acetazolamide but, in addition, they are well absorbed topically so that they can be used as drugs for treating glaucoma.

  与乙酰唑胺及其N-甲基衍生物相关的化合物，其化学式为：其中Y是以下组之一：R.sub.1是直链或支链烷基或芳基烷基，或苯基，以及它们的制备方法；所得的化合物是碳酸酐酶抑制剂，类似于乙酰唑胺，但另外，它们在局部吸收良好，因此可以用作治疗青光眼的药物。
• Discovery of Novel Thieno[2,3-d]pyrimidin-4-yl Hydrazone-Based Cyclin-Dependent Kinase 4 Inhibitors: Synthesis, Biological Evaluation and Structure-Activity Relationships
  作者：Takao Horiuchi、Yasuyuki Takeda、Noriyasu Haginoya、Masaki Miyazaki、Motoko Nagata、Mayumi Kitagawa、Kouichi Akahane、Kouichi Uoto

  DOI：10.1248/cpb.59.991

  日期：——

  The design, synthesis, and evaluation of novel thieno[2,3-d]pyrimidin-4-yl hydrazone analogues as cyclin-dependent kinase 4 (CDK4) inhibitors are described. In continuing our program aim to search for potent CDK4 inhibitors, the introduction of a thiazole group at the hydrazone part has led to marked enhancement of chemical stability. Furthermore, by focusing on the optimization at the C-4' position

  描述，设计和合成新型噻吩并[2,3-d]嘧啶-4-基类似物作为细胞周期蛋白依赖性激酶4（CDK4）抑制剂。在继续我们的计划以寻找有效的CDK4抑制剂的过程中，在part部分引入噻唑基团导致化学稳定性显着提高。此外，通过集中于噻唑环的C-4'位置和噻吩并[2,3-d]嘧啶部分的C-6位置的优化，已确定化合物35在HCT116异种移植模型中有效细胞。在本文中，我们对合成化合物的效价，选择性和结构活性关系进行了讨论。
• Palladium-Catalyzed Site-Selective Fluorination of Unactivated C(sp³)–H Bonds
  作者：Jinmin Miao、Ke Yang、Martin Kurek、Haibo Ge

  DOI：10.1021/acs.orglett.5b01710

  日期：2015.8.7

  The transition-metal-catalyzed direct C–H bond fluorination is an attractive synthetic tool toward the preparation of organofluorines. While many methods exist for the direct sp3 C–H functionalization, site-selective fluorination of unactivated sp3 carbons remains a challenge. Direct, highly site-selective and diastereoselective fluorination of aliphatic amides via a palladium-catalyzed bidentate ligand-directed

  过渡金属催化的直接C–H键氟化是制备有机氟的有吸引力的合成工具。尽管存在许多直接进行sp 3 C–H官能化的方法，但未活化的sp 3碳的位点选择性氟化仍然是一个挑战。据报道，通过钯催化的双齿配体定向的C–H键官能化过程，可以在未活化的sp 3碳上进行直接，高度位点选择性和非对映选择性的氟化。用这种方法，以乙酸钯为催化剂，Selectfluor为氟源，制备了多种在医学和农业化学中重要的基序的β-氟化氨基酸衍生物和脂族酰胺。
• Synthesis of new Amides based on N-Phthaloyl-α-Amino Acids
  作者：Davlat Tukhtaev、Alisher Yusupov、Valentina Vinogradova

  DOI：10.21608/ejchem.2021.48494.2990

  日期：2021.3.5

  N-phthaloyl derivatives of aliphatic α-amino acids were synthesized using phthalanhydride under standard conditions. The optimization reaction carried out by the thermal method to obtain the amides of these N-phthaloyl amino acids resulted in transimitted rather than amidation. The target amides of N-phthaloyl-α-amino acids were obtained by acylation of the amine with the corresponding acid chloroanhydrides in dichloromethane. These results were compared with the results of a similar acylation in a non-polar solvent (benzene). The dependence of the direction of the reaction on the duration of the acylation and the amount of amine used was established. The conditions for the formation of the corresponding N-phthaloyl-α-amino acid amides and asymmetric phthalic acid diamides were found. It is noteworthy that the formation of diamides is directly proportional to the equivalent amount of amine and the duration of the reaction, which makes it possible to purposefully control the synthesis in one reactor.

  N-邻苯二甲酰基碳链α-氨基酸的衍生物在标准条件下采用邻苯二甲酰酸酐合成。通过热方法优化反应以获得这些N-邻苯二甲酰基氨基酸的酰胺，结果显示转化倾向于而非氨基化。N-邻苯二甲酰基-α-氨基酸的目标酰胺通过在二氯甲烷中与相应的酸氯酐进行酰化获得。这些结果与在非极性溶剂（苯）中进行的类似酰化结果进行了比较。确定了反应方向依赖于酰化持续时间和所用氨基的量。还找到了相应的N-邻苯二甲酰基-α-氨基酸酰胺和不对称邻苯二甲酸二酰胺的形成条件。值得注意的是，二酰胺的形成与氨基的等效量和反应时间呈正比，这使得能够在一个反应器中有针对性地控制合成。
• Structural optimization of 4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f]-[1,2,4]triazolo[4,3-a][1,4]diazepines as antagonists for platelet activating factor: pharmacological contribution of substituents at the 2- and 6-positions of a condensed ring system
  作者：Y Kawakami、H Kitani、S Yuasa、M Abe、M Moriwaki、M Kagoshima、M Terasawa、T Tahara

  DOI：10.1016/0223-5234(96)85877-6

  日期：1996.1

  A series of 4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives bearing substituents at the 2- and 6-positions were synthesized, and evaluated in vitro for their inhibitory activity on rabbit platelet aggregation induced by platelet activating factor (PAF) and in vivo for their preventing effect on PAF-induced mortality in mice. The length of alkyl or arylalkyl side chain at the 2-position was responsible for enhancing the affinity for the PAF receptor. The simultaneous substitution at both the 2- and 6-positions resulted in a successful separation of the affinity for the PAF receptor from that for the benzodiazepine (BZ) receptor. Thus, (+/-)-4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine (Y-24180) was confirmed to be a specific antagonist for the PAF receptor and is currently under clinical trials.